An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
Status:
Recruiting
Trial end date:
2024-08-20
Target enrollment:
Participant gender:
Summary
Sickle cell disease (SCD) is a genetic blood disorder. Crizanlizumab has been approved in
India and other countries to reduce the frequency of vaso-occlusive crises (VOCs) in patients
with SCD aged 16 years and older.
The purpose of this local Phase IV study is to evaluate the safety of crizanlizumab
specifically in Indian patients with SCD aged 16 years or older with a history of VOC leading
to healthcare visit.